Table 4. SUCRA-Based Primary Efficacy and Safety Outcome Rankings from Normotensive RCTs.
| Primary safety outcome rankings | ||||
|---|---|---|---|---|
| Intervention | Primary efficacy | Dry cough | Presyncope | Peripheral edema |
| outcome ranking* | ranking* | ranking* | ranking* | |
| ACEI | - | - | - | - |
| Candesartan | 3 | - | - | - |
| Captopril | 9 | 1 | - | - |
| Enalapril | 5 | - | - | - |
| Enalapril+losartan | 6 | - | - | - |
| Lisinopril | 4 | - | - | - |
| Lisinopril+losartan | 8 | - | - | - |
| Losartan | 7 | - | 2 | - |
| Nifedipine | 12 | - | - | - |
| Ramipril | 13 | 2 | - | - |
| Trandolapril | 2 | - | - | - |
| Trandolapril+candesartan+cilexetil | 1 | - | - | - |
| Valsartan | 11 | - | - | - |
*Placebo was ranked 10th in the primary efficacy outcome, was ranked 3rd in the cough safety outcome, was ranked 1st in the presyncope safety outcome, and was not ranked in the peripheral edema safety outcome.